Across TCGA pan-cancer cohorts, ANKRD46 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ANKRD46 data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher ANKRD46 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ANKRD46 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

LSCC, LUAD, and CCRCC are the cancer types where ANKRD46 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	All	0.892	0.213	.010	6	view →
LUAD	DFS	Median	III,IV	0.922	0.409	.024	4	view →
CCRCC	DFS	Median	All	0.862	0.640	.020	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: ANKRD46 tumor-vs-normal RNA expression · all ANKRD46 data types